Triple Moving Average Crossover
|Bid||7.67 x 1800|
|Ask||7.73 x 1200|
|Day's Range||7.30 - 7.90|
|52 Week Range||5.61 - 76.77|
|Beta (5Y Monthly)||1.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 07, 2023 - Aug 11, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.00|
Subscribe to Yahoo Finance Plus to view Fair Value for NVAXLearn more
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novavax Inc's (NASDAQ: NVAX) R&D chief Filip Dubovsky expressed confidence that the company's updated COVID-19 vaccine, already in production, will offer protection against the rapidly emerging coronavirus variants prevalent in the U.S. Novavax's protein-based vaccines, although slower to manufacture than the mRNA-based vaccines developed by Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE)/BioNTech SE (NASDAQ: BNTX), are promising in targeting the evolving strains. In an annual general meet
Europe's medicine regulators on Tuesday backed the World Health Organization's recommendation to update the antigen composition of COVID-19 vaccines to target one of the currently dominant XBB variants ahead of the upcoming autumn vaccination campaign. Advisory groups related to the WHO suggested that, while waiting for more data, the monovalent XBB-containing vaccines could be considered a reasonable choice and individuals at risk of progression to severe disease such as older adults should be given priority, according to European Centre for Disease Prevention and Control (ECDC) and European Medicines Agency (EMA).
Novavax Inc's head of research and development on Monday said an updated COVID-19 vaccine the company is already producing is likely to be protective against other fast-growing coronavirus variants circulating in the U.S. Protein-based vaccines like Novavax's take longer to produce than the messenger RNA-based (mRNA) versions made by Moderna and Pfizer/BioNTech. A panel of outside advisers to the U.S. Food and Drug Administration is scheduled to meet on June 15 to discuss strain selection for this year's COVID-19 booster shots, and regulators are expected to make their decision shortly afterward.
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has signed a three-year agreement with the Bill & Melinda Gates Medical Research Institute to provide its adjuvant for use in preclinical vaccine research.
Novavax stock is on the rise after announcing a cost-cutting plan and bullish sales guidance. Is NVAX stock a buy or a sell today?
Summer is in full swing. June can be a great time of the year. It’s time to go to the beach, catch some rays and unwind. But if you’ve got F-rated stocks to sell in your portfolio, June won’t be fun for you at all unless you take some swift action. Historically, June isn’t a great month for the stock market. On average, the stock market has been flat during June – a far cry from November, December and April, when the market does better. That’s not to say you need to empty your portfolio this mon
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in the Jefferies Global Healthcare Conference.
Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.
Health authorities and vaccine makers are moving toward targeting the next shot on a form of the XBB strain that is now circulating widely in the U.S.
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that Nuvaxovid™ (NVX-CoV2373) has been recommended for full Marketing Authorization (MA) for use as a primary series in individuals aged 12 and older and as a booster in individuals aged 18 and older for the prevention of COVID-19 in the European Union (EU) following a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the Europea
Wall Street has high hopes for certain stocks over the coming 12 months. Two of them are biotech companies that took center stage during earlier days of the pandemic. Both companies raced to bring a coronavirus vaccine to market.
One of the places to find the best stocks to short are by viewing the Short Interest tables of major financial publications like MarketWatch and the Wall Street Journal. It’s there you find the heavily shorted stocks in the markets. As Investopedia states, “Short interest is the number of shares that have been sold short and remain outstanding.” When the short interest rises for an individual stock, it could indicate that investors are souring on that stock. The inverse applies when the short in
The world’s foremost artificial intelligence stock trading algorithm, An-E, predicts that Novavax (NASDAQ:NVAX) stock will gain 7% by June 15. An-E (pronounced Annie) has made this kind of prediction before. Back in December, Wall Street was bullish on Johnson & Johnson (NYSE:JNJ). Analysts were convinced JNJ could only go up… but An-E knew better. The algorithm said that JNJ stock was headed down 10% over one month… and JNJ stock fell that exact amount. Wall Street was shocked… but An-E saw it
There's been lots of excitement surrounding Novavax (NASDAQ: NVAX). Cash burn is a big concern for a company such as Novavax, which is likely to see its revenue decline as demand for its COVID-19 vaccine dwindles. As of the end of March, the company had $625 million in cash and cash equivalents on the books -- down by more than half from more than $1.3 billion it reported at the end of 2022.
Select analysts believe three former high-flying stocks can make their shareholders significantly richer.
On May 9, Novavax (NASDAQ: NVAX) shareholders got a much-needed reprieve from the stock's downward trajectory over the last year. Novavax's decline is a regrettable one. Its coronavirus vaccine candidate ran into regulatory issues during clinical development, and arrived on the market much later than those of competitors like Pfizer and Moderna.
The World Health Organization recently announced covid is no longer a global emergency. Hooray! That is unless you're Novavax, the biotech outfit...
Shareholders in Novavax, Inc. ( NASDAQ:NVAX ) may be thrilled to learn that the analysts have just delivered a major...
Novavax (NASDAQ: NVAX) investors have been on edge ever since the company fell behind in the coronavirus vaccine race. To make matters worse, earlier this year, Novavax even questioned its ability to continue operations. Jacobs revealed details about his strategy to cut costs, manage cash flow, and match Novavax's size to the demand for its only product: the coronavirus vaccine.
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Singapore Health Sciences Authority (HSA) has granted extended interim authorization and the Ministry of Health has included Nuvaxovid™ (NVX-CoV2373) into the National Vaccination Programme as a non-mRNA option for adolescents aged 12 through 17 for active immunization to prevent COVID.
In the early days of the COVID-19 pandemic, Novavax (NASDAQ: NVAX) took center stage. The biotech company became one of the first to enter clinical trials with a coronavirus vaccine candidate. Novavax's vaccine launched a year after those of the company's rivals, meaning Novavax missed out on the biggest revenue opportunity.
Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.
A Biotech Company Developing Vaccines and a Restaurant Stock with Earnings Growth.
Yahoo Finance health care reporter Anjalee Khemlani details Novavax's latest earnings report.